{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:52:01Z","timestamp":1792461121550,"version":"4.5.0"},"reference-count":31,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background: We analyzed data from a cohort of 553 women enrolled in the placebo arm of a randomized controlled trial of the human papillomavirus (HPV) 16\/18 vaccine to study the timing of the occurrence of squamous intraepithelial lesions (SIL) or cervical intraepithelial neoplasia (CIN) following incident HPV infection and its relation to persistence of the infection.<\/jats:p>\n               <jats:p>Methods: At entry, women were cytologically negative, HPV 16\/18 seronegative, and high-risk HPV (HR-HPV) DNA negative. Cervicovaginal samples were initially collected at 3-month and cervical samples at 6-month intervals. We estimated the mean time to SIL\/CIN, relative risks of SIL\/CIN following incident HPV, and odds ratios between persistent HPV and SIL\/CIN.<\/jats:p>\n               <jats:p>Results: The mean time for SIL\/CIN detection was 43.3 [95% confidence interval (95% CI), 36.4-50.1] and 46.4 (95% CI, 42.0-50.7) months from first infection with HPV 16\/18 and other HR-HPVs, respectively. Relative risks of SIL\/CIN following incident HPV infection were 66.2 (95% CI, 14.9-295.1) for HPV 16\/18 and 50.9 (95% CI, 11.5-225.4) for other HR-HPVs. The odds ratios of SIL\/CIN for persistent HPV 16\/18 infection, defined as a minimum of two and three (6 monthly) visits, were, respectively, 169.0 (95% CI, 37.2-768.6) and 169.1 (95% CI, 31.5-907.4). The majority of women with cervical infection with HPV 16\/18 lasting &amp;gt;6 months (33 of 51, 65%) developed SIL and\/or CIN.<\/jats:p>\n               <jats:p>Conclusions: These analyses provide the first actuarial estimate of mean time between incident HR-HPV infection in previously uninfected women and onset of cervical lesion development. Persistent HR-HPV infection, particularly HPV 16\/18, is a strong predictor of cervical lesion risk and potentially a reliable end point for clinical HPV research. (Cancer Epidemiol Biomarkers Prev 2009;18(3):854\u201362)<\/jats:p>","DOI":"10.1158\/1055-9965.epi-08-1012","type":"journal-article","created":{"date-parts":[[2009,3,9]],"date-time":"2009-03-09T07:27:41Z","timestamp":1236583661000},"page":"854-862","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Persistence of an Incident Human Papillomavirus Infection and Timing of Cervical Lesions in Previously Unexposed Young Women"],"prefix":"10.1158","volume":"18","author":[{"given":"Helen","family":"Trottier","sequence":"first","affiliation":[{"name":"1Division of Cancer Epidemiology, McGill University, Montreal, Quebec, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salaheddin M.","family":"Mahmud","sequence":"additional","affiliation":[{"name":"2Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Lindsay","sequence":"additional","affiliation":[{"name":"3GlaxoSmithKline Biologicals, Rixensart, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jenkins","sequence":"additional","affiliation":[{"name":"3GlaxoSmithKline Biologicals, Rixensart, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Quint","sequence":"additional","affiliation":[{"name":"5DDL Diagnostic Laboratories, Voorburg, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Wieting","sequence":"additional","affiliation":[{"name":"3GlaxoSmithKline Biologicals, Rixensart, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Schuind","sequence":"additional","affiliation":[{"name":"4GlaxoSmithKline Biologicals, King of Prussia, Pennsylvania; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo L.","family":"Franco","sequence":"additional","affiliation":[{"name":"1Division of Cancer Epidemiology, McGill University, Montreal, Quebec, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the GSK HPV-001 Vaccine Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2009,3,9]]},"reference":[{"key":"2022061000215557200_BIB1","doi-asserted-by":"crossref","unstructured":"Mun\u0303oz N, Bosch FX, de Sanjose\u0301 S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med\u20082003;348:518\u201327.","DOI":"10.1056\/NEJMoa021641"},{"key":"2022061000215557200_BIB2","doi-asserted-by":"crossref","unstructured":"de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology\u20082004;324:17\u201327.","DOI":"10.1016\/j.virol.2004.03.033"},{"key":"2022061000215557200_BIB3","doi-asserted-by":"crossref","unstructured":"Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol\u20082005;6:204.","DOI":"10.1016\/S1470-2045(05)70086-3"},{"key":"2022061000215557200_BIB4","doi-asserted-by":"crossref","unstructured":"Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol\u20081999;189:12\u20139.","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F"},{"key":"2022061000215557200_BIB5","doi-asserted-by":"crossref","unstructured":"Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis\u20082005;191:1808\u201316.","DOI":"10.1086\/428779"},{"key":"2022061000215557200_BIB6","doi-asserted-by":"crossref","unstructured":"Wallin KL, Wiklund F, Angstrom T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med\u20081999;341:1633\u20138.","DOI":"10.1056\/NEJM199911253412201"},{"key":"2022061000215557200_BIB7","doi-asserted-by":"crossref","unstructured":"Kjaer SK, van den Brule AJ, Paull G, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ\u20082002;325:572.","DOI":"10.1136\/bmj.325.7364.572"},{"key":"2022061000215557200_BIB8","doi-asserted-by":"crossref","unstructured":"Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA\u20082001;286:3106\u201314.","DOI":"10.1001\/jama.286.24.3106"},{"key":"2022061000215557200_BIB9","doi-asserted-by":"crossref","unstructured":"Bosch FX, Lorincz A, Mun\u0303oz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol\u20082002;55:244\u201365.","DOI":"10.1136\/jcp.55.4.244"},{"key":"2022061000215557200_BIB10","doi-asserted-by":"crossref","unstructured":"Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol\u20082000;19:1\u20135.","DOI":"10.1016\/S1386-6532(00)00125-6"},{"key":"2022061000215557200_BIB11","doi-asserted-by":"crossref","unstructured":"Cuschieri KS, Cubie HA, Whitley MW, et al. Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J Clin Pathol\u20082005;58:946\u201350.","DOI":"10.1136\/jcp.2004.022863"},{"key":"2022061000215557200_BIB12","doi-asserted-by":"crossref","unstructured":"Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst\u20081995;87:1365\u201371.","DOI":"10.1093\/jnci\/87.18.1365"},{"key":"2022061000215557200_BIB13","doi-asserted-by":"crossref","unstructured":"Crum CP, McLachlin CM. Cervical intraepithelial neoplasia. J Cell Biochem Suppl\u20081995;23:71\u20139.","DOI":"10.1002\/jcb.240590910"},{"key":"2022061000215557200_BIB14","doi-asserted-by":"crossref","unstructured":"Bory JP, Cucherousset J, Lorenzato M, et al. Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women. Int J Cancer\u20082002;102:519\u201325.","DOI":"10.1002\/ijc.10735"},{"key":"2022061000215557200_BIB15","doi-asserted-by":"crossref","unstructured":"Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis\u20082005;191:182\u201392.","DOI":"10.1086\/426867"},{"key":"2022061000215557200_BIB16","doi-asserted-by":"crossref","unstructured":"Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst\u20082002;94:1406\u201314.","DOI":"10.1093\/jnci\/94.18.1406"},{"key":"2022061000215557200_BIB17","doi-asserted-by":"crossref","unstructured":"Dalstein V, Riethmuller D, Pretet JL, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer\u20082003;106:396\u2013403.","DOI":"10.1002\/ijc.11222"},{"key":"2022061000215557200_BIB18","doi-asserted-by":"crossref","unstructured":"Evander M, Edlund K, Gustafsson A, et al. Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis\u20081995;171:1026\u201330.","DOI":"10.1093\/infdis\/171.4.1026"},{"key":"2022061000215557200_BIB19","doi-asserted-by":"crossref","unstructured":"Franco E, Villa L, Rohan T, Ferenczy A, Petzl-Erler M, Matlashewski G. Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Ludwig-McGill Study Group. Rev Panam Salud Publica\u20081999;6:223\u201333.","DOI":"10.1590\/S1020-49891999000900001"},{"key":"2022061000215557200_BIB20","doi-asserted-by":"crossref","unstructured":"Giuliano AR, Harris R, Sedjo RL, et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. J Infect Dis\u20082002;186:462\u20139.","DOI":"10.1086\/341782"},{"key":"2022061000215557200_BIB21","doi-asserted-by":"crossref","unstructured":"Herrero R, Schiffman MH, Bratti C, et al. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica\u20081997;1:362\u201375.","DOI":"10.1590\/S1020-49891997000500005"},{"key":"2022061000215557200_BIB22","doi-asserted-by":"crossref","unstructured":"Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA\u20082001;285:2995\u20133002.","DOI":"10.1001\/jama.285.23.2995"},{"key":"2022061000215557200_BIB23","unstructured":"Xi LF, Carter JJ, Galloway DA, et al. Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. Cancer Epidemiol Biomarkers Prev\u20082002;11:343\u201351."},{"key":"2022061000215557200_BIB24","doi-asserted-by":"crossref","unstructured":"Koshiol JE, Lindsay L, Pimenta JM, Poole CL, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol\u20082008;168:123\u201337.","DOI":"10.1093\/aje\/kwn036"},{"key":"2022061000215557200_BIB25","doi-asserted-by":"crossref","unstructured":"Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet\u20082004;364:1757\u201365.","DOI":"10.1016\/S0140-6736(04)17398-4"},{"key":"2022061000215557200_BIB26","doi-asserted-by":"crossref","unstructured":"Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet\u20082006;367:1247\u201355.","DOI":"10.1016\/S0140-6736(06)68439-0"},{"key":"2022061000215557200_BIB27","doi-asserted-by":"crossref","unstructured":"Jenkins D. Histopathology and cytopathology of cervical cancer. Dis Markers\u20082007;23:199\u2013212.","DOI":"10.1155\/2007\/874795"},{"key":"2022061000215557200_BIB28","doi-asserted-by":"crossref","unstructured":"Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med\u20081992;327:1272\u20138.","DOI":"10.1056\/NEJM199210293271804"},{"key":"2022061000215557200_BIB29","doi-asserted-by":"crossref","unstructured":"Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis\u20082005;191:731\u20138.","DOI":"10.1086\/427557"},{"key":"2022061000215557200_BIB30","doi-asserted-by":"crossref","unstructured":"Ault KA; Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet\u20082007;369:1861\u20138.","DOI":"10.1016\/S0140-6736(07)60852-6"},{"key":"2022061000215557200_BIB31","doi-asserted-by":"crossref","unstructured":"Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet\u20082007;369:2161\u201370.","DOI":"10.1016\/S0140-6736(07)60946-5"}],"container-title":["Cancer Epidemiology, Biomarkers &amp; Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cebp\/article-pdf\/18\/3\/854\/2269352\/854.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cebp\/article-pdf\/18\/3\/854\/2269352\/854.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T06:15:05Z","timestamp":1654841705000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cebp\/article\/18\/3\/854\/164730\/Persistence-of-an-Incident-Human-Papillomavirus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,1]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2009,3,9]]},"published-print":{"date-parts":[[2009,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1055-9965.epi-08-1012","relation":{},"ISSN":["1055-9965","1538-7755"],"issn-type":[{"value":"1055-9965","type":"print"},{"value":"1538-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,1]]}}}